Private Eye

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

CEO buying at BriaCell Therapeutics (T:BCT)

Updated Friday Aug 11, 2017 01:23 AM EDT

William Williams, CEO and Director, acquired 4,058,441 Common Shares on a direct ownership basis at a price of $0.160 through a private transaction on August 9th, 2017. This represents a $649,351 investment into the company's shares and an account share holdings change of 70.8%.

BriaCell Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company. The Company is engaged in the research and development of cancer immunotherapy technology. The Company offers BriaVax, an immunotherapy vaccine. The Company is engaged in developing and advancing its BriaVax immunotherapy vaccine for patients with advanced breast cancer. The Company is also engaged in the research and development of its companion diagnostic product, BriaDx. The Company's BriaDx program is focused on analyzing samples obtained from patients previously treated with BriaVax along with co-analysis of previously manufactured vaccine lots. The Company's analysis methods include various technologies, including gene expression profiling by Illumina microarrays and human leukocyte antigen (HLA) typing by a high-resolution method. The Company is focused on understanding the mechanism of action (MoA) of BriaVax.

INK Edge Outlook

CONDITIONS:
Latest
6 months ago
1 year ago
Overall
Rain
Mixed
Mostly Sunny
The INK Edge Outlook is a quantitative process that ranks a stock based on our V.I.P. criteria.
View outlooks on all Canadian listed stocks at inkresearch.com.
Two-week free trial for first time users.
Go to BriaCell Therapeutics Corp. (BCT)'s company page

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Comment On!

No Comments

Twitter

Search (past week) for $BCT.CA

  • No tweets found

Stocktwits